Literature DB >> 11682403

A comparison of patient-controlled sedation using either remifentanil or remifentanil-propofol for shock wave lithotripsy.

H S Joo1, W J Perks, M T Kataoka, L Errett, K Pace, R J Honey.   

Abstract

UNLABELLED: Patient-controlled sedation (PCS) has been used for extracorporeal shock wave lithotripsy (SWL) because it allows for rapid individualized titration of anesthetics. Because of its sedating effects, the addition of propofol to remifentanil may improve patient tolerance of SWL with PCS. One hundred twenty patients were randomly assigned to receive remifentanil 10 microg or remifentanil 10 microg plus propofol 5 mg for PCS with zero-lockout interval. Nine patients in the Remifentanil group and three patients in the Remifentanil-Propofol group required additional sedatives to complete their SWL (P = 0.128). Compared with the Remifentanil group, the Remifentanil-Propofol group required less remifentanil, had a decreased incidence of postoperative nausea and vomiting, and had a better overall satisfaction level. However, they had an increased incidence of transient apnea and oxygen desaturation. The incidence of apnea was 15% in the Remifentanil group and 52% in the Remifentanil-Propofol group (P < 0.001). All patients were able to move themselves to the stretcher at the end of SWL, and median time to home discharge was <70 min in both groups. Both remifentanil and remifentanil-propofol were useful for PCS during SWL. IMPLICATIONS: The addition of propofol to remifentanil improves patient satisfaction and decreases postoperative nausea and vomiting. However, it causes more respiratory depression than remifentanil alone. When remifentanil-propofol is used with patient-controlled sedation, appropriate monitoring and a minimum 1-2 min lockout interval is required.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682403     DOI: 10.1097/00000539-200111000-00037

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Comparison of propofol-remifentanil versus propofol-ketamine deep sedation for third molar surgery.

Authors:  Kyle J Kramer; Steven Ganzberg; Simon Prior; Robert G Rashid
Journal:  Anesth Prog       Date:  2012

2.  Comparison of dexmedetomidine and midazolam for monitored anesthesia care combined with tramadol via patient-controlled analgesia in endoscopic nasal surgery: A prospective, randomized, double-blind, clinical study.

Authors:  Kazim Karaaslan; Fahrettin Yilmaz; Nebahat Gulcu; Cemil Colak; Murat Sereflican; Hasan Kocoglu
Journal:  Curr Ther Res Clin Exp       Date:  2007-03

3.  Patient-controlled sedation with propofol/remifentanil versus propofol/alfentanil for patients undergoing outpatient colonoscopy, a randomized, controlled double-blind study.

Authors:  Sherif S Sultan
Journal:  Saudi J Anaesth       Date:  2014-11

4.  Comparison of the effects of patient controlled analgesia (PCA) using dexmedetomidine and propofol during septoplasty operations: a randomized clinical trial.

Authors:  Başak Akça; Ayhan Arslan; Aysun Ankay Yılbaş; Özgür Canbay; Nalan Çelebi
Journal:  Springerplus       Date:  2016-05-10

5.  Procedural sedation and analgesia for respiratory-gated MR-HIFU in the liver: a feasibility study.

Authors:  Johanna M M van Breugel; Joost W Wijlemans; Hermanus H B Vaessen; Martijn de Greef; Chrit T W Moonen; Maurice A A J van den Bosch; Mario G Ries
Journal:  J Ther Ultrasound       Date:  2016-07-29

6.  The comparison of sedation quality, side effect and recovery profiles on different dosage of remifentanil patient-controlled sedation during breast biopsy surgery.

Authors:  Jin-Deok Joo; Jang Hyeok In; Dae-Woo Kim; Hong Soo Jung; Jae Hyeok Kang; Je Hwa Yeom; Jin Woo Choi
Journal:  Korean J Anesthesiol       Date:  2012-11-16

7.  The analgesic effect of inhalational Entonox for extracorporeal shock wave lithotripsy.

Authors:  Hamid Mazdak; Parvaneh Abazari; Fatemeh Ghassami; Shekoofeh Najafipour
Journal:  Urol Res       Date:  2007-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.